Browse our collection of papers in
GlaxoSmithKline (GSK)
C/OM/197. Innovation Audit: Use of Molecular Clinical Safety Intelligence System by GlaxoSmithKline
- WORDS:
- 1400
- DATE:
- 2010
- PRICE:
- 19.99 GBP
The paper looks at the Molecular Clinical Safety Intelligence (MCSI), a unique intelligent knowledge management system used by GlaxoSmithKline (GSK) to screen potential candidates and identify possible health issues prior to clinical development. Organisational context of GSK is described, their investment in innovative technologies is discussed, the importance of MCSI system for the development of new drugs is highlighted.
KEYWORDS: Molecular Clinical Safety Intelligence, MCSI, Innovation, GlaxoSmithKline, GSK, Pharmaceutical, new drugs development,
Other Papers On: GlaxoSmithKline (GSK)
Other Papers On: Innovation
Subject Catalogue
- Dissertations and Proposals
- Analysis of Companies
- Analysis of Industries
- Architecture, Design and Technology
- Computing and Mathematics
- E-Commerce and E-Business
- Economics
- Education
- Engineering
- Fashion and Culture
- Finance and Accounting
- General Business
- History
- Hospitality and Tourism
- Human Resource Management
- International Relations
- Law
- Literature, Language and Theatre Studies
- Management and Organisational Behaviour
- Marketing
- Media, Music and Art
- Operations Management
- Philosophy
- Politics
- Psychology
- Science, Medicine and Nursing
- Sociology
Keywords Tag Cloud
glaxosmithkline gsk management merger dissertation pharmaceutical mergers change strategic om plc performance glaxo beecham financial wellcome corporate operations smithkline desired bring acquisition study effects proposal market system social stock strategy glaxowellcome quality value global vs organisational astrazeneca managing johnson impact model equilibrium technical newspaper construction disclosures environmental glaxosmithklein publicity using british pre pharmaceuticals acquisitions petroleum post smithline prediction annual pestel stocks swine intelligence safety clinical molecular shoeshine directions novartis pfizer companies audit innovation vaccines flu portfolio production uk healthcare responsibility faced issues reports control implementation valuation development role lean price critical process speeding share innovations intellectual systems soft critique knowledge methodology harbin project property negotiation approach backgrounds entrepreneurship announcement effect master return glaxosmithklines final culture benefit economic finance international risk c comparative benefits current position investigation overview options company
GET OUR GooGLE TOOLBAR BUTTON
BOOK MARK US
WHAT OTHERS HAVE SAID
I received the paper very fast and it helped me quite a lot. ThanksPatel
